This site is intended for health professionals only

FDA approve drug for treatment of HIV


The US Food and Drug Administration (FDA) have approved Complera for the treatment of HIV.

Complera is a fixed dose combination drug containing emtricitabine (200mg), rilpivirine (25mg) and tenofovir (300mg). The recommended dose is one tablet per day, taken orally with a meal and the drug is indicated for the treatment of human immunodeficiency virus type 1 (HIV 1) infection in antiretroviral treatment, with naïve adult patients.

“[Complera] is a complete regimen for tackling HIV infection in treatment naïve patients because it contains a Nonnucleoside Reverse Transcriptase Inhibitor (rilpivirine) and two Nucleoside Reverse Transcriptase Inhibitors (emtricitabine and tenofovir DF),” said a statement on FDA’s website.

The following points should be considered when initiating therapy with Complera, according to the organisation:

¥    More rilpivirine-treated subjects with HIV-1 RNA greater than 100,000 copies/mL at the start of therapy experienced virologic failure compared to subjects with HIV-1 RNA less than 100,000 copies/mL at the start of therapy.

¥    The observed virologic failure rate in rilpivirine-treated subjects conferred a higher rate of overall treatment resistance and cross-resistance to the Nonnucleoside Reverse Transcriptase Inhibitor class compared to efavirenz.

¥    More subjects treated with rilpivirine developed lamivudine/emtricitabine-associated resistance compared to efavirenz.


Be in the know
Subscribe to Hospital Pharmacy Europe newsletter and magazine